LSD vs Mushrooms: Comparing Psychedelic Effects of LSD, Psilocybin and Mescaline
Acute subjective effects reported by healthy individuals given moderate-to-high doses of three psychedelics were extremely similar.
Lysergic acid diethylamide (LSD), psilocybin (the psychoactive compound in “magic mushrooms”) and mescaline are three of the most widely studied classic psychedelics. Each has a long history of cultural use and growing interest in clinical research. Understanding the similarities and differences between LSD vs mushrooms vs mescaline is essential for guiding safe and effective therapeutic applications.
According to a study published in the journal Neuropsychopharmacology, there are no significant differences in the effects of LSD, mescaline or psilocybin when given at equivalent doses.
The study directly compared the effects of the three psychedelics in a randomized, double-blind, placebo-controlled crossover trial. The researchers found that the acute subjective effects reported by healthy individuals given moderate-to-high doses of the drugs were extremely similar; many participants were unable to identify the drug given at any one administration session.
Given the similarity between the altered states of consciousness caused by the drugs at equivalent doses, the researchers say that the dosing information contained in this trial could be useful evidence for future dose-finding studies for psychedelic-assisted therapy.
Different psychedelic trips show strong similarities
A total of 32 healthy volunteers were enrolled in this study to determine the difference between LSD vs mushrooms vs mescaline, which took place over five sessions in a hospital environment.
At each session, baseline physiological measurements were taken before participants were given either a moderate-to-high dose of mescaline, LSD, or psilocybin or an equivalent placebo medication designed to be visually identical to active drugs. Following administration, each participant was kept in the hospital for around 25 hours for further observations.
Credit: iStock.
Each participant was asked at regular intervals to rate various aspects of their experience according to multiple validated assessment scales, which included:
- Adjective Mood Rating Scale – evaluating mood dimensions.
- 5 Dimensions of Altered States of Consciousness scale – quantifying perceptual and cognitive changes.
- States of Consciousness Questionnaire – assessing mystical-type experiences.
Continuous physiological monitoring of the following metrics was conducted in the 24 hours following drug administration to ensure safety and gather comparative data:
- Blood pressure
- Heart rate
- Pupil diameter
- Body temperature.
Participants were asked to provide blood samples at baseline, 1.5, 3 and 6 hours after administration, which were assessed for any changes in plasma oxytocin concentration.
LSD vs mushrooms vs mescaline
The researchers found that the subjective acute drug effects were rated similarly by the study participants across all three drugs. The physical effects of the drugs were also similar, with two exceptions: psilocybin induced significantly higher readings in diastolic blood pressure compared to LSD, while LSD showed a trend towards an increased heart rate compared with psilocybin.
The largest difference between LSD vs mushrooms vs mescaline was their pharmacokinetics and the associated duration of the high (Table 1). The acute effects of the mescaline lasted the longest, followed by LSD, then psilocybin. The researchers determined that mescaline took significantly longer than LSD to reach its maximal plasma concentration and subjective effects. But once this maximum concentration was reached, the drug was eliminated from the body at the same rate as LSD, meaning they had similar comedowns.
“These pharmacokinetic differences between the two substances may be the only clinically relevant pharmacological distinctions between mescaline and LSD,” the researchers wrote.
Table 1. A comparison of the effects of LSD vs mushrooms (psilocybin) vs mescaline
| Parameter | LSD (100 µg) | Psilocybin (20 mg) | Mescaline (500 mg) |
| Primary Receptor Target | 5-HT2A, 5-HT1A, dopamine (D1-3) | 5-HT2A, serotonin transporter inhibition | 5-HT2A, 5-HT1A, α2A adrenergic |
| Subjective Experience | Profound, mystical, perceptual | Similar to LSD | Similar to LSD |
| Duration of Effects | ~8–12 hours | ~4–6 hours | ~12–14 hours |
| Physiological Changes | Trend toward higher heart rate | Higher diastolic blood pressure | Comparable to LSD and psilocybin |
| Peak Plasma Concentration | Moderate onset | Rapid onset | Delayed onset |
Dose, not substance, may matter more
Mescaline, LSD and psilocybin have notable differences in terms of which receptors they interact with. While they all bind to the serotonin 5-HT2A receptors, which is considered the primary driver of their hallucinogenic effects, mescaline also binds to the 5-HT1A and adrenergic α2A receptors, while LSD acts against the 5-HT2B/2C, 5-HT1A and dopamine D1-3 receptors. Psilocin (the active metabolite of psilocybin) acts on the 5-HT2A receptor, but also simultaneously inhibits the serotonin transporter.
Despite these differences, the current study shows that the drugs have similar subjective effects on humans. This may suggest that dosing and the desired duration of action could be the most important factors when it comes to choosing a psychedelic for use in psychedelic-assisted therapy sessions or similar applications.
Addressing Drug-Induced Liver Injury Using Adaptable Liver Model Systems
This webinar explores how liver microphysiological systems support toxicology from early screening to species-specific risk assessment study design and mechanistic insight into drug-induced liver injury in humans.View Webinar
“We found no evidence of qualitative differences in altered states of consciousness that were induced by 500 mg mescaline, 100 µg LSD, and 20 mg psilocybin,” the researchers wrote. “This study supports dose finding for research and psychedelic-assisted therapy.”
In a previous study, several researchers from the same group also found no significant differences in the psychedelic trip when comparing equivalent moderate and high doses of LSD vs mushrooms (psilocybin).
“These findings indicate that any differences in alterations of consciousness that are induced by mescaline, LSD, and psilocybin are dose-dependent rather than substance-dependent and that their distinct pharmacological profiles do not have a relevant influence on the subjective experience,” the researchers wrote in their paper.
“The present study further supports the view that all three substances primarily exert their psychedelic effects through agonistic activity at 5-HT2A receptors.”
Broader impact on psychedelic research
The debate of LSD vs mushrooms often centers on perceived differences in the quality of the psychedelic experience. However, controlled laboratory evidence shows that LSD, psilocybin and mescaline produce remarkably similar subjective effects at equivalent doses. The most relevant distinctions arise from pharmacokinetics and duration of action, which could help inform future therapy design.
As psychedelic research advances, such head-to-head comparisons will remain crucial in bridging laboratory pharmacology and clinical application. The evidence suggests that while receptor profiles differ, the lived psychedelic experience depends largely on dosage and session length rather than the specific compound administered.
This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
